Baird analyst Michael Ha raised the firm’s price target on Universal Health to $274 from $236 and keeps an Outperform rating on the shares. The firm reiterated the shares as its top hospital pick as 2Q performance confirmed their margin recovery thesis with nearly 15% 2Q adj. EBITDA margins; the highest since 2021), and they believe this is only the beginning of a powerful multi-year margin improvement story.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UHS:
- Universal Health price target raised to $255 from $200 at Wells Fargo
- Universal Health upgraded to Overweight from Equal Weight at Barclays (Friday)
- Universal Health price target raised to $220 from $183 at TD Cowen
- Universal Health upgraded to Neutral from Underweight at Cantor Fitzgerald
- Universal Health upgraded to Overweight from Equal Weight at Barclays